Author + information
- Samuel Goldhaber,
- Walter Ageno,
- Ivan Casella,
- Kok Han Chee,
- Sebastian Schellong,
- Daniel E. Singer,
- Isabelle Voccia,
- Wenbo Tang and
- Sam Schulman
RE-COVERY DVT/PE is a multicenter, international, observational study of patients with deep vein thrombosis/pulmonary embolism (DVT/PE), comparing outcomes with dabigatran vs. vitamin K antagonists (VKAs).
The main outcomes were International Society on Thrombosis and Haemostasis major or clinically relevant nonmajor bleeding events (MBE/CRNMBE) and symptomatic recurrent venous thromboembolism (VTE), including VTE-related mortality up to 12 months after diagnosis. To account for variation in patient characteristics, only patients in an overlapping range of estimated propensity scores were included (restricted set). Patients who completed or discontinued their initial anticoagulant were censored at the date of last drug intake + 6 days or at first intake of another relevant anticoagulant, whichever occurred first.
A total of 3,009 patients were eligible: 60% had a diagnosis of DVT alone, 21% had PE alone and 19% had DVT plus PE. The restricted set consisted of 2,969 patients: 1,681 receiving dabigatran and 1,288 receiving VKAs. The overall incidence rate (%/year [95% CI]) of MBE/CRNMBEs was 2.6 (1.8-3.7) vs. 4.5 (3.2-6.1) with dabigatran vs. VKAs, and symptomatic VTE/related mortality was 1.5 (0.9-2.4) vs. 2.0 (1.2-3.1), respectively. The Table shows Kaplan-Meier estimates at 12 months and the statistical comparison of treatments.
Dabigatran had a favorable safety profile in routine clinical practice, reflecting results seen in clinical trials.
Sunday, March 29, 2020, 8:25 a.m.-8:35 a.m.
Session Title: Highlighted Original Research: Vascular Medicine and the Year in Review
Abstract Category: 41. Vascular Medicine: Venous Disease
Presentation Number: 906-06
- 2020 American College of Cardiology Foundation